RELATED PRODUCTS NOT AVAILABLE
Designed to deliver large volumeb and/or high viscosityc fixed dose subcutaneous injection.1
The BD Libertas™ Wearable Injector is designed as a pre-fillable drug delivery system for combination products.1
The BD Libertas™ Wearable Injector is an innovative injection system designed to deliver complex biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations, at home or in clinical settings.1
BD Libertas™ Wearable Injector features a mechanical spring-based power source, without battery or heavy metals disposal concerns.1, 2
BD reinforced its commitment to innovation by completing a 52-subject human clinical trial for its award-winningd 2-5 mL BD Libertas™ Wearable Injector.3
BD Libertas™ Wearable Injector - Introductory overview video
BD Libertas™ Wearable Injector Features
BD Libertas™ Wearable Injector Benefits
a BD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification.
b 2-5 mL or 5-10 mL.
c up to 50 cP.
d BD Libertas™ Wearable Injector and DCA Design International have won two design awards: the Good Design® Award and the iF Design Excellence Award.
e Designed to inject the drug therapy hands-free once activated
f Needle retracts automatically upon injection completion without additional user steps.
BD has conducted over 50 BD pre-clinical4 and clinical5 studies to inform the design and development of the BD Libertas™ Wearable Injector, demonstrate feasibility of 2-10 mL biologic injections into subcutaneous tissue and characterize tissue response to large volume injections in human and animal subjects.3
BD conducted a 52-subject human clinical trial with the BD Libertas™ Wearable Injector that evaluated the performance of the 2-5 mL device, including tissue effects, tolerability (pain) and patient acceptance.3 100% of study subjects likely to use if prescribed.g,3
Results of this human clinical trial are published in Clinical and Translational Science.3
Additional BD research into large volume subcutaneous injections may be found in another published clinical study in the peer reviewed journal Clinical and Translational Science. This additional translational feasibility study examined an expanded range of volumes and viscosities (up to 10ml & 20cP) using delivery from a surrogate syringe pump and without co-delivery of a permeation enhancer in 32 healthy adult subjects.
a BD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification.
b 2-5 mL or 5-10 mL.
c up to 50 cP.
g Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5 mL, non-Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects of ≥18.5kg/m2 BMI divided into 2 age groups (18-64 or ≥65 years) for functionality, tissue effects, subject tolerability and acceptability.
a BD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification.
b 2-5 mL or 5-10 mL.
c up to 50 cP.
a BD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification.
b 2-5 mL or 5-10 mL.
c up to 50 cP.
View collected literature about BD offerings and our industry for information you can use to continue striving for excellence.
a BD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification.
b 2-5 mL or 5-10 mL.
c up to 50 cP.